Midza (Lacosamide)

Lacosamide, the active ingredient in Midza, is an anticonvulsant presented as an oral tablet for oral use. It is indicated for the treatment of partial‑onset seizures and is used as adjunctive therapy in patients with epilepsy. It is formulated for systemic absorption and is marketed across the European Union. The product meets stringent regulatory requirements for safety and efficacy.

GNH USA supplies Midza as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU quality standards and providing reliable global distribution.

Lacosamide is an anticonvulsant that acts on neuronal sodium channels to control seizure activity.

- Partial‑onset seizures: reduces the frequency and severity of focal seizures. - Adjunctive therapy for epilepsy: enhances seizure control when added to existing antiepileptic regimens. - Epilepsy (generalized): may be employed as part of a broader treatment plan under specialist guidance.

Lacosamide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Nausea: mild to moderate stomach upset. - Headache: transient cranial discomfort. - Fatigue: unusual tiredness or lack of energy. - Blurred vision: temporary visual disturbances. - Diplopia: double vision in some patients.

Serious or Rare Side Effects: - Suicidal ideation: emergence of thoughts of self‑harm. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Cardiac arrhythmias: including PR‑interval prolongation. - Respiratory depression: marked reduction in breathing effort, especially when combined with other CNS depressants.

When prescribing or dispensing Lacosamide, clinicians should consider several safety measures.

- Cardiac monitoring: assess ECG for PR‑interval changes before initiation. - Renal function: adjust dosing in patients with impaired clearance. - Concomitant CNS depressants: evaluate additive sedation risk. - Patient counseling: advise on dizziness and advise against operating machinery until tolerance is known. - Discontinuation: avoid abrupt cessation to prevent seizure rebound. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lacosamide can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase lacosamide plasma levels. - Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin): may reduce lacosamide exposure. - Other sodium‑channel blockers (e.g., lamotrigine): increase risk of CNS depression. - Alcohol: potentiates dizziness and sedation.

Moderate Interactions (Monitor Closely): - Antihypertensives: additive hypotensive effect may require dose adjustment. - Oral contraceptives: lacosamide may reduce hormonal efficacy, consider alternative contraception. - Other antiepileptics (e.g., valproate): may necessitate therapeutic drug monitoring.